A Phase 2 interventional study of etonogestrel implant in HIV/AIDS and Contraception, sponsored by Catherine Anne Chappell. Completed at 1 site in Uganda. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Catherine Anne Chappell · Phase 2, Interventional, and Treatment
Among 120 studies in Acquired Immunodeficiency Syndrome with a site in Uganda — 16 open to participants now, 23 under way, 5 of them phase 3. Acquired Immunodeficiency Syndrome · Uganda.
Among the 120 studies in Acquired Immunodeficiency Syndrome with a site in Uganda, this one is the 83rd largest by enrollment of the 102 interventional ones, is one of 8 that started in 2019, is one of 8 in phase 2, and was the 57th registered.
3,035 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 306 are open to participants now.
This study's enrollment of 72 is below the median of 96 across 2,251 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →16 of the 120 studies in Acquired Immunodeficiency Syndrome with a site in Uganda are open now, in 12 countries. Each count lists the studies.
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →120 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2019.
Median enrollment 387 across the 102 interventional studies, 350 across the 18 observational. Of the 86 that completed or were terminated, 34 (40%) have results posted.
13 of 120 have an industry lead sponsor. The 10 most frequent:
Catherine Anne Chappell is the lead sponsor of 3 studies on the registry; none are open to participants now.
Catherine Anne Chappell has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Acquired Immunodeficiency Syndrome with a site in Uganda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071623Phase 3Merck Sharp & Dohme LLCA Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | 2027-10-18 |
| NCT05373758Massachusetts General HospitalA Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa | 2027-06-30 |
| NCT07840651Makerere UniversityIntegrating Tuberculosis Treatment Into Community Pharmacies to Improve TB/HIV Outcomes in Uganda | 2027-09 |
Among the 120 studies in Acquired Immunodeficiency Syndrome with a site in Uganda, from their registry updates:
This study will evaluate the frequency of ovulation and cervical mucus quality of HIV-infected Ugandan women on efavirenz-based antiretroviral therapy using either a single etonogestrel implant or two etonogestrel implants for at least one year.
This study is being done to compare the rate of ovulation when women receive two subdermal implant contraception devices containing the hormone etonogestrel (instead of only one device) while taking the HIV drug efavirenz. The etonogestrel implant is a device that is inserted under the skin on the upper arm and releases a small amount of drug into the body every day over a long period of time to prevent pregnancy for 3 years. A total of 72 non-pregnant women in Uganda, who agree to use the copper intrauterine device throughout the study, will participate in this study. Half will be assigned by chance to use one implant and half will be assigned to use two implants at the entry visit. After the entry visit to place the implant, visits will be scheduled 1 week, 4 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 21 weeks, 22, weeks, 23 weeks, 24 weeks, 36 weeks, 45 weeks, 46 weeks, 47 weeks, and 48 weeks after the implant(s) were placed. The rate of ovulation (determined by weekly endogenous progesterone concentrations in the blood during months 3, 6, and 12) will be compared between women that receive two 68 mg etonogestrel implants compared to one 68 mg etonogestrel implant in combination with efavirenz-based antiretroviral therapy. Cervical mucus quality (from cervical mucus samples collected weekly at months 3, 6, and 12), the blood concentration of etonogestrel (from blood samples collected at day 3 and weeks 1, 4, 12, 24, 36, 48) and efavirenz (from blood samples collected at enrollment and weeks 4, 12, 24, 36, 48, and the number of adverse events deemed related to etonogestrel implant use through 48 weeks will also be compared between the one- and two-implant study arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 68 mg etonogestrel implant
Drug: etonogestrel implant
Two 68 mg (136 mg total) etonogestrel implants
Drug: etonogestrel implant
The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
Also known as: Nexplanon, Implanon
Proportion of Participants That Ovulate During Month 3
Proportion of participants that experience at least one ovulation during month 3 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 3 (weeks 9-12). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
Time frame: 3 months
Proportion of Participants That Ovulate During Month 6
Proportion of participants that experience at least one ovulation during month 6 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 6 (weeks 21-24). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
Time frame: 6 months
Proportion of Participants That Ovulate During Month 12
Proportion of participants that experience at least one ovulation during month 12 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 12 (weeks 45-48). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
Time frame: 12 months
Proportion of Cervical Mucus Scores Greater Than 10
The proportion of World Health Organization cervical mucus scores that are greater than 10 from weekly samples collected during months 3, 6 and 12 of etonogestrel implant use. A cervical mucus score greater than 10 indicates the mucus is favorable for sperm penetration or lack of contraceptive effect. The cervical mucus score ranges from 0 indicating least favorable for sperm penetration to 15 for most favorable for sperm penetration.
Time frame: 12 months
Median Efavirenz Concentration at Enrollment
Median efavirenz concentrations measured in plasma samples collected at enrollment, prior to insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: Day 0
Median Efavirenz Concentration at Week 4
Median efavirenz concentrations measured in plasma samples collected 4 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: 4 weeks
Median Efavirenz Concentration at Week 12
Median efavirenz concentrations measured in plasma samples collected 12 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: 12 weeks
Median Efavirenz Concentration at Week 24
Median efavirenz concentrations measured in plasma samples collected 24 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: 24 weeks
Median Efavirenz Concentration at Week 36
Median efavirenz concentrations measured in plasma samples collected 36 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: 36 weeks
Median Efavirenz Concentration at Week 48
Median efavirenz concentrations measured in plasma samples collected 48 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
Time frame: 48 weeks
Median Etonogestrel Concentration at Week 1
Median etonogestrel concentrations measured in plasma samples collected 1 week after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 1 week
Median Etonogestrel Concentration at Week 4
Median etonogestrel concentrations measured in plasma samples collected 4 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 4 weeks
Median Etonogestrel Concentration at Week 12
Median etonogestrel concentrations measured in plasma samples collected 12 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 12 weeks
Median Etonogestrel Concentration at Week 24
Median etonogestrel concentrations measured in plasma samples collected 24 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 24 weeks
Median Etonogestrel Concentration at Week 36
Median etonogestrel concentrations measured in plasma samples collected 36 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 36 weeks
Median Etonogestrel Concentration at Week 48
Median etonogestrel concentrations measured in plasma samples collected 48 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
Time frame: 48 weeks
| Milestone | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Started | 36 | 36 |
| Completed | 34 | 36 |
| Not completed | 2 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
Proportion of participants that experience at least one ovulation during month 3 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 3 (weeks 9-12). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
| Participants | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Proportion of Participants That Ovulate During Month 3 | 11 | 0 |
Proportion of participants that experience at least one ovulation during month 6 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 6 (weeks 21-24). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
| Participants | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Proportion of Participants That Ovulate During Month 6 | 17 | 0 |
Proportion of participants that experience at least one ovulation during month 12 of etonogestrel implant use. Serum progesterone concentrations are measured weekly during month 12 (weeks 45-48). Ovulation is defined as endogenous progesterone concentrations of \>3 ng/mL.
| Participants | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Proportion of Participants That Ovulate During Month 12 | 19 | 2 |
The proportion of World Health Organization cervical mucus scores that are greater than 10 from weekly samples collected during months 3, 6 and 12 of etonogestrel implant use. A cervical mucus score greater than 10 indicates the mucus is favorable for sperm penetration or lack of contraceptive effect. The cervical mucus score ranges from 0 indicating least favorable for sperm penetration to 15 for most favorable for sperm penetration.
| Cervical mucus samples | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Cervical mucus score greater than 10 | 1 | 1 |
| Cervical mucus score of 10 or less | 248 | 233 |
Median efavirenz concentrations measured in plasma samples collected at enrollment, prior to insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Enrollment | 2.26 (1.15 to 4.63) | 2.30 (1.28 to 3.65) |
Median efavirenz concentrations measured in plasma samples collected 4 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Week 4 | 2.41 (1.47 to 4.26) | 2.23 (1.38 to 5.46) |
Median efavirenz concentrations measured in plasma samples collected 12 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Week 12 | 2.10 (1.22 to 3.99) | 1.88 (1.35 to 2.87) |
Median efavirenz concentrations measured in plasma samples collected 24 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Week 24 | 2.26 (1.31 to 4.12) | 1.76 (1.18 to 3.47) |
Median efavirenz concentrations measured in plasma samples collected 36 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Week 36 | 1.97 (1.18 to 5.27) | 1.87 (1.09 to 4.28) |
Median efavirenz concentrations measured in plasma samples collected 48 weeks after insertion of the etonogestrel implant(s). Plasma efavirenz concentrations were quantified using a high-performance liquid chromatography assay with ultraviolet detection.
| µg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Efavirenz Concentration at Week 48 | 2.05 (1.36 to 3.66) | 1.72 (1.01 to 2.73) |
Median etonogestrel concentrations measured in plasma samples collected 1 week after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 1 | 182 (102 to 303) | 439 (327 to 618) |
Median etonogestrel concentrations measured in plasma samples collected 4 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 4 | 115 (79 to 178) | 282 (158 to 414) |
Median etonogestrel concentrations measured in plasma samples collected 12 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 12 | 83 (66 to 99) | 214 (124 to 271) |
Median etonogestrel concentrations measured in plasma samples collected 24 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 24 | 69 (41 to 99) | 168 (91 to 224) |
Median etonogestrel concentrations measured in plasma samples collected 36 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 36 | 54 (42 to 71) | 132 (75 to 157) |
Median etonogestrel concentrations measured in plasma samples collected 48 weeks after insertion of the etonogestrel implant(s). Plasma etonogestrel concentrations were quantified using liquid chromatography tandem mass spectrometry.
| pg/mL | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| Median Etonogestrel Concentration at Week 48 | 39 (25 to 64) | 95 (69 to 137) |
Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Dose Etonogestrel Implant | 0/36 (0%) | 0/36 (0%) | 35/36 (97.2%) |
| Increased Dose Etonogestrel Implant | 0/36 (0%) | 0/36 (0%) | 35/36 (97.2%) |
| Event | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant |
|---|---|---|
| MenorrhagiaReproductive system and breast disorders | 23/36 | 30/36 |
| Implant Site ReactionProduct Issues | 15/36 | 24/36 |
| MetrorrhagiaReproductive system and breast disorders | 14/36 | 22/36 |
| HeadacheNervous system disorders | 16/36 | 15/36 |
| DysmenorrheaReproductive system and breast disorders | 8/36 | 10/36 |
| AcneSkin and subcutaneous tissue disorders | 9/36 | 6/36 |
| Breast TendernessReproductive system and breast disorders | 1/36 | 4/36 |
| NauseaGastrointestinal disorders | 4/36 | 4/36 |
| AmenorrheaReproductive system and breast disorders | 2/36 | 3/36 |
| Weight GainGeneral disorders | 1/36 | 3/36 |
All enrolled participants
| Age, Continuous(years) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Median | 32 (28 to 36) | 30 (29 to 35) | 31 (29 to 36) |
| Sex: Female, Male(Participants) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Female | 36 | 36 | 72 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Ganda | 22 | 19 | 41 |
| Nkore | 5 | 1 | 6 |
| Nyarwanda | 2 | 3 | 5 |
| Soga | 2 | 1 | 3 |
| Tooro | 0 | 3 | 3 |
| Kiga | 1 | 3 | 4 |
| Other | 4 | 6 | 10 |
| Region of Enrollment(participants) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Uganda | 36 | 36 | 72 |
| Weight(kg) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Median | 60.2 (54.0 to 69.1) | 59.2 (51.0 to 70.5) | 60.0 (52.6 to 69.4) |
| CD4+ cell count(cells/mm3) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Median | 648 (602 to 923) | 700 (536 to 875) | 669 (547 to 880) |
| Prior live births(births) | Standard Dose Etonogestrel Implant | Increased Dose Etonogestrel Implant | Total |
|---|---|---|---|
| Median | 3 (2.25 to 4) | 3 (2 to 3.75) | 3 (2 to 4) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Dec 2020, 22 months.
Results were first posted in Sep 2024, 3 years 8 months after primary completion.
Of 57 non-industry phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's 22 months is below that.
Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etonogestrel
Acquired Immunodeficiency Syndrome →
Catherine Anne Chappell